Feasibility of Prospectively Comparing Opioid Analgesia With Opioid-Free Analgesia After Outpatient General Surgery
Authors: Uyen Do, Charbel El-Kefraoui, Makena Pook, Saba Balvardi, Natasha Barone, Philip Nguyen-Powanda, Lawrence Lee, Gabriele Baldini, Liane S. Feldman, Julio F. Fiore, Mohsen Alhashemi, Alen Antoun, Jeffrey S. Barkun, Krista M. Brecht, Prosanto K. Chaudhury, Dan Deckelbaum, Elise Di Lena, Sinziana Dumitra, Hiba Elhaj, Paola Fata, David Fleiszer, Gerald M. Fried, Jeremy Grushka, Pepa Kaneva, Kosar Khwaja, Maxime Lapointe-Gagner, Katherine M. McKendy, Ari N. Meguerditchian, Sarkis H. Meterissian, Haley Montgomery, Fateme Rajabiyazdi, Nadia Safa, Nawar Touma, Francine Tremblay
Journal: JAMA Network Open (2022)

<h3>Importance</h3> The overprescription of opioids to surgical patients is recognized as an important factor contributing to the opioid crisis. However, the value of prescribing opioid analgesia (OA) vs opioid-free analgesia (OFA) after postoperative discharge remains uncertain. <h3>Objective</h3> To investigate the feasibility of conducting a full-scale randomized clinical trial (RCT) to assess the comparative effectiveness of OA vs OFA after outpatient general surgery. <h3>Design, Setting, and Participants</h3> This parallel, 2-group, assessor-blind, pragmatic pilot RCT was conducted from January 29 to September 3, 2020 (last follow-up on October 2, 2020). at 2 university-affiliated hospitals in Montreal, Quebec, Canada. Participants were adult patients (aged ≥18 years) undergoing outpatient abdominal (ie, cholecystectomy, appendectomy, or hernia repair) or breast (ie, partial or total mastectomy) general surgical procedures. Exclusion criteria were contraindications to drugs used in the trial, preoperative opioid use, conditions that could affect assessment of outcomes, and intraoperative or early complications requiring hospitalization. <h3>Interventions</h3> Patients were randomized 1:1 to receive OA (around-the-clock nonopioids and opioids for breakthrough pain) or OFA (around-the-clock nonopioids with increasing doses and/or addition of nonopioid medications for breakthrough pain) after postoperative discharge. <h3>Main Outcomes and Measures</h3> Main outcomes were a priori RCT feasibility criteria (ie, rates of surgeon agreement, patient eligibility, patient consent, treatment adherence, loss to follow-up, and missing follow-up data). Secondary outcomes included pain intensity and interference, analgesic intake, 30-day unplanned health care use, and adverse events. Between-group comparison of outcomes followed the intention-to-treat principle. <h3>Results</h3> A total of 15 surgeons were approached; all (100%; 95% CI, 78%-100%) agreed to have patients recruited and adhered to the study procedures. Rates of patient eligibility and consent were 73% (95% CI, 66%-78%) and 57% (95% CI, 49%-65%), respectively. Seventy-six patients were randomized (39 [51%] to OA and 37 [49%] to OFA) and included in the intention-to-treat analysis (mean [SD] age, 55.5 [14.5] years; 50 [66%] female); 40 (53%) underwent abdominal surgery, and 36 (47%) underwent breast surgery. Seventy-five patients (99%; 95% CI, 93%-100%) adhered to the allocated treatment; 1 patient randomly assigned to OFA received an opioid prescription. Seventeen patients (44%) randomly assigned to OA consumed opioids after discharge. Seventy-three patients (96%; 95% CI, 89%-99%) completed the 30-day follow-up. The rate of missing questionnaires was 37 of 3724 (1%; 95% CI, 0.7%-1.4%). All the a priori RCT feasibility criteria were fulfilled. <h3>Conclusions and Relevance</h3> The findings of this pilot RCT support the feasibility of conducting a robust, full-scale RCT to inform evidence-based prescribing of analgesia after outpatient general surgery. <h3>Trial Registration</h3> ClinicalTrials.gov Identifier:NCT04254679